StockNews.AI
SAGE
StockNews.AI
203 days

Sage Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025

1. SAGE will host a webcast on February 11, 2025. 2. Webcast will cover Q4 and full year 2024 financial results. 3. SAGE focuses on innovative brain health therapies. 4. Two FDA-approved treatments for postpartum depression highlight SAGE's pipeline strength. 5. Replay of the webcast will be available for 30 days.

Earnings
-0.27%Current Return
VS
-0.45%S&P 500
$7.3501/28 05:42 PM EDTEvent Start
$7.3301/30 12:17 AM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Neutral?

While the webcast provides updates, it doesn’t indicate immediate market changes for SAGE.

How important is it?

Financial results can influence stock prices, but are typical disclosures.

Why Short Term?

The results discussed may affect short-term investor sentiment but are less impactful long-term.

Related Companies

SAGE
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), today announced that it will host a live webcast on Tuesday, February 11, 2025 at 4:30 p.m. ET to review fourth quarter and full year 2024 financial results and discuss recent business updates. The webcast can be accessed on the Investor page of Sage’s website at investor.sagerx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. About Sage Therapeutics Sage Therapeutics (Nasdaq: SAGE) is a biopharmaceutical company committed to our mission of pioneering solutions to deliver life-changing brain health medicines, so every person can thrive. Sage developed the only two FDA-approved treatments indicated for postpartum depression and is advancing a pipeline to target unmet needs in brain health. Sage was founded in 2010 and is headquartered in Cambridge, Mass. Find out more at www.sagerx.com or engage with us on Facebook, LinkedIn, Instagram, and X.

Related News